Enalaprilato na prevenção da hipertrofia ventricular esquerda induzida pelo isoproterenol

Costa, Eduardo A. S.; Fo, Bráulio Luna; Póvoa, Rui; Fo, Celso Ferreira; Murad, Neif; Ferreira, Marcelo; Ferreira, Celso

doi:10.1590/s0066-782x1997000700006

Cited by 5 publications

(4 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The investigations included in Table 1 demonstrate the relevance of angiotensin-converting enzyme (ACE) inhibitors14,15,22–24 and angiotensin antagonist25 treatment for cardiac hypertrophy regression.…”

Section: Resultsmentioning

confidence: 99%

“…In particular, ACE inhibitors have shown promising cardio-protective effects in experimental models of hypertensive heart disease;22 specifically, these inhibitors improve micro-vascular ischemia, ventricular function and arrhythmias 14–16, 23–29. We have previously reported that enalapril14 (ACE inhibitor) and verapamil23 (Ca ++ channel blocker) provide the same cardio-protector response in an isoproterenol-induced LVH model in rats 28…”

Section: Discussionmentioning

confidence: 99%

“…Therefore, LVH is a powerful predictor of cardiovascular morbidity and mortality 3. Clinical and experimental studies have reported that several pharmacological, hemodynamic and non-hemodynamic factors are able to induce, reverse and prevent LVH,14–16 interstitial fibrosis17 and the progression of atherosclerotic effects on myocytes 18. Clinically, cardiac hypertrophy is associated with increased adverse events, including stroke, chronic renal failure, ventricular dysfunction, ventricular arrhythmias and sudden death 3.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Anti-Hypertensive Drugs Have Different Effects on Ventricular Hypertrophy Regression

Ferreira

Abreu

Valenti

et al. 2010

Clinics

Self Cite

View full text Add to dashboard Cite

OBJECTIVES:There is a direct relationship between the regression of left ventricular hypertrophy (LVH) and a decreased risk of mortality. This investigation aimed to describe the effects of anti-hypertensive drugs on cardiac hypertrophy through a meta-analysis of the literature.METHODS:The Medline (via PubMed), Lilacs and Scielo databases were searched using the subject keywords cardiac hypertrophy, antihypertensive and mortality. We aimed to analyze the effect of anti-hypertensive drugs on ventricle hypertrophy.RESULTS:The main drugs we described were enalapril, verapamil, nifedipine, indapamina, losartan, angiotensin-converting enzyme inhibitors and atenolol. These drugs are usually used in follow up programs, however, the studies we investigated used different protocols. Enalapril (angiotensin-converting enzyme inhibitor) and verapamil (Ca++ channel blocker) caused hypertrophy to regress in LVH rats. The effects of enalapril and nifedipine (Ca++ channel blocker) were similar. Indapamina (diuretic) had a stronger effect than enalapril, and losartan (angiotensin II receptor type 1 (AT1) receptor antagonist) produced better results than atenolol (selective β1 receptor antagonist) with respect to LVH regression.CONCLUSION:The anti-hypertensive drugs induced various degrees of hypertrophic regression.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Anti-Hypertensive Drugs Have Different Effects on Ventricular Hypertrophy Regression

Ferreira

Abreu

Valenti

et al. 2010

Clinics

Self Cite

View full text Add to dashboard Cite

show abstract

“…Hypertrophic cardiomyopathy may be defined as myocardial involvement without definitive etiology, characterized by left ventricle hypertrophy (rarely right ventricle), with myofibrillar disorder, increased left ventricular ejection fraction and decreased cardiac output, which depends on the functional impairment degree [41-47]. The outflow tract obstruction may exist or not.…”

Section: Discussionmentioning

confidence: 99%

Sudden cardiac death athletes: a systematic review

Ferreira

Silva

Abreu

et al. 2010

BMC Sports Sci Med Rehabil

Self Cite

View full text Add to dashboard Cite

Previous events evidence that sudden cardiac death (SCD) in athletes is still a reality and it keeps challenging cardiologists. Considering the importance of SCD in athletes and the requisite for an update of this matter, we endeavored to describe SCD in athletes. The Medline (via PubMed) and SciELO databases were searched using the subject keywords "sudden death, athletes and mortality". The incidence of SCD is expected at one case for each 200,000 young athletes per year. Overall it is resulted of complex dealings of factors such as arrhythmogenic substrate, regulator and triggers factors. In great part of deaths caused by heart disease in athletes younger than 35 years old investigations evidence cardiac congenital abnormalities. Athletes above 35 years old possibly die due to impairments of coronary heart disease, frequently caused by atherosclerosis. Myocardial ischemia and myocardial infarction are responsible for the most cases of SCD above this age (80%). Pre-participatory athletes' evaluation helps to recognize situations that may put the athlete's life in risk including cardiovascular diseases. In summary, cardiologic examinations of athletes' pre-competition routine is an important way to minimize the risk of SCD.

show abstract

Repeated dose of meloxicam induces genotoxicity and histopathological changes in cardiac tissue of mice

Silva

Dallegrave²,

Rodrigues

et al. 2020

Drug and Chemical Toxicology

View full text Add to dashboard Cite

Enalaprilato na prevenção da hipertrofia ventricular esquerda induzida pelo isoproterenol

Abstract: Enalaprilat inhibited the isoproterenol action on the cardiomyocite, avoiding partially the LVH and decreasing the content of collagen fibers.

Cited by 5 publications

References 19 publications

Anti-Hypertensive Drugs Have Different Effects on Ventricular Hypertrophy Regression

Anti-Hypertensive Drugs Have Different Effects on Ventricular Hypertrophy Regression

Sudden cardiac death athletes: a systematic review

Repeated dose of meloxicam induces genotoxicity and histopathological changes in cardiac tissue of mice

Contact Info

Product

Resources

About